Skip to main content
. 2024 Apr 22;14(11):100981. doi: 10.1016/j.jpha.2024.100981

Fig. 7.

Fig. 7

Therapeutic efficacy of hyaluronic acid (HA)-modified hybrid membrane (M)-camouflaged poly lactic-co-glycolic acid (PLGA) loaded halofuginone hydrobromide (HF) nanoparticles (NPs) (HA-M@P@HF NPs) in vivo. (A, B) Paw swelling volume (A) and arthritis severity scores (B) in adjuvant-induced arthritis (AIA) rats injected with saline (normal), methotrexate (MTX), HF (0.25 mg/kg), PLGA, or HA-M@P@HF NPs (HF 0.25 mg/kg) (n = 6 per formulation). (C, D) Hematoxylin-eosin (H&E) staining (C) and histopathological synovial score (HSS) (D) of the synovial joints. The star means immune cell infiltration and the red arrow means angiogenesis. (E, F) Masson staining (E) and score (F) of the synovial joints. (G, H) Safranin O-fast green (SO-FG) staining (G) and cartilage damage score (H) of the ankle joints. The black arrow means cartilage damage. (I, J) Micro-computed tomography (CT) (I) and bone destruction score (J) of normal control, AIA rats, and different treatment groups. Data are presented as mean ± standard deviation (n = 3). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.